Frontiers in Immunology (Dec 2022)
STXBP3 and GOT2 predict immunological activity in acute allograft rejection
- Qinfan Yao,
- Qinfan Yao,
- Qinfan Yao,
- Qinfan Yao,
- Cuili Wang,
- Cuili Wang,
- Cuili Wang,
- Cuili Wang,
- Yucheng Wang,
- Yucheng Wang,
- Yucheng Wang,
- Yucheng Wang,
- Wenyu Xiang,
- Wenyu Xiang,
- Wenyu Xiang,
- Wenyu Xiang,
- Yin Chen,
- Yin Chen,
- Yin Chen,
- Yin Chen,
- Qin Zhou,
- Qin Zhou,
- Qin Zhou,
- Qin Zhou,
- Jianghua Chen,
- Jianghua Chen,
- Jianghua Chen,
- Jianghua Chen,
- Hong Jiang,
- Hong Jiang,
- Hong Jiang,
- Hong Jiang,
- Dajin Chen,
- Dajin Chen,
- Dajin Chen,
- Dajin Chen
Affiliations
- Qinfan Yao
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Qinfan Yao
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Qinfan Yao
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Qinfan Yao
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Cuili Wang
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Cuili Wang
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Cuili Wang
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Cuili Wang
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Yucheng Wang
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Yucheng Wang
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Yucheng Wang
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Yucheng Wang
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Wenyu Xiang
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Wenyu Xiang
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Wenyu Xiang
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Wenyu Xiang
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Yin Chen
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Yin Chen
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Yin Chen
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Yin Chen
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Qin Zhou
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Qin Zhou
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Qin Zhou
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Qin Zhou
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Jianghua Chen
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Jianghua Chen
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Jianghua Chen
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Jianghua Chen
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Hong Jiang
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Hong Jiang
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Hong Jiang
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Hong Jiang
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Dajin Chen
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Dajin Chen
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Dajin Chen
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Dajin Chen
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- DOI
- https://doi.org/10.3389/fimmu.2022.1025681
- Journal volume & issue
-
Vol. 13
Abstract
BackgroundAcute allograft rejection (AR) following renal transplantation contributes to chronic rejection and allograft dysfunction. The current diagnosis of AR remains dependent on renal allograft biopsy which cannot immediately detect renal allograft injury in the presence of AR. In this study, sensitive biomarkers for AR diagnosis were investigated and developed to protect renal function.MethodsWe analyzed pre- and postoperative data from five databases combined with our own data to identify the key differently expressed genes (DEGs). Furthermore, we performed a bioinformatics analysis to determine the immune characteristics of DEGs. The expression of key DEGs was further confirmed using the real-time quantitative PCR (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemical (IHC) staining in patients with AR. ROC curves analysis was used to estimate the performance of key DEGs in the early diagnosis of AR.ResultsWe identified glutamic-oxaloacetic transaminase 2 (GOT2) and syntaxin binding protein 3 (STXBP3) as key DEGs. The higher expression of STXBP3 and GOT2 in patients with AR was confirmed using RT-qPCR, ELISA, and IHC staining. ROC curve analysis also showed favorable values of STXBP3 and GOT2 for the diagnosis of early stage AR.ConclusionsSTXBP3 and GOT2 could reflect the immunological status of patients with AR and have strong potential for the diagnosis of early-stage AR.
Keywords
